Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

We should be hearing soon about the revised Ponatinib label. Once we get that validation of Ponatinib's long term efficacy I think investors will recognize what most of here already understand. That is, Ponatinib's best days are ahead as its unparalleled ability to defeat multiple forms of cancer is now being understood and, more importantly, the management and mitigation of the vascular SAEs caused by Ponatinib are finally being realized by careful controls on dosing and patient selection. All this should create increased investor response especially as Brigatinib is on the cusp of approval. I would not be surprised to see December and the 1st quarter of 2017 to be the most productive period for the sp since the months preceding the Ponatinib approval. High teens to 20 are realistic by the April approval imo. Thank you Denner!